These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1889633)

  • 21. Spurious drugs.
    Mittal SB
    J Indian Med Assoc; 2000 Aug; 98(8):464. PubMed ID: 11294333
    [No Abstract]   [Full Text] [Related]  

  • 22. Results from a bench marking survey on Supporting Chemical Synthesis and Structural Elucidation in the Pharmaceutical Industry.
    Peake DA; Ackermann BL
    J Am Soc Mass Spectrom; 2005 Apr; 16(4):599-605. PubMed ID: 15871168
    [No Abstract]   [Full Text] [Related]  

  • 23. Patents and the quality, safety and efficacy of medicines.
    du Toit K; du Preez W; Padayachee S
    S Afr Med J; 2015 Nov; 105(11):905-6. PubMed ID: 26632315
    [No Abstract]   [Full Text] [Related]  

  • 24. Industrial biotransformations in the synthesis of building blocks leading to enantiopure drugs.
    Muñoz Solano D; Hoyos P; Hernáiz MJ; Alcántara AR; Sánchez-Montero JM
    Bioresour Technol; 2012 Jul; 115():196-207. PubMed ID: 22230779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large-scale oxidations in the pharmaceutical industry.
    Caron S; Dugger RW; Ruggeri SG; Ragan JA; Ripin DH
    Chem Rev; 2006 Jul; 106(7):2943-89. PubMed ID: 16836305
    [No Abstract]   [Full Text] [Related]  

  • 27. Standards and dental suppliers.
    Simmonds H
    Br Dent J; 1999 Mar; 186(5):210. PubMed ID: 10205962
    [No Abstract]   [Full Text] [Related]  

  • 28. The balance to be achieved between in-process controls and finished product testing.
    Hutton RC
    Boll Chim Farm; 1986 Jul; 125(7):221-7. PubMed ID: 3801165
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug-drug interactions related to altered absorption and plasma protein binding: theoretical and regulatory considerations, and an industry perspective.
    Hochman J; Tang C; Prueksaritanont T
    J Pharm Sci; 2015 Mar; 104(3):916-29. PubMed ID: 25557998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the Committee on Safety of Drugs.
    Mansel-Jones D
    Br Med Bull; 1970 Sep; 26(3):257-9. PubMed ID: 4922462
    [No Abstract]   [Full Text] [Related]  

  • 31. Firms take another step to stop counterfeits.
    Thompson CA
    Am J Health Syst Pharm; 2003 Jun; 60(11):1090, 1095. PubMed ID: 12816017
    [No Abstract]   [Full Text] [Related]  

  • 32. Comment on: developing good scientific publishing practices: one pharmaceutical company's perspective.
    Norris RA
    Curr Med Res Opin; 2010 Jul; 26(7):1675-6. PubMed ID: 20450261
    [No Abstract]   [Full Text] [Related]  

  • 33. Company's attempt to switch its patients to a new drug is foiled.
    Dyer O
    BMJ; 2014 Dec; 349():g7802. PubMed ID: 25537279
    [No Abstract]   [Full Text] [Related]  

  • 34. Upon closer inspection. As the U.S. imports more drugs and devices, the FDA's overseas initiatives aim to head off trouble at the source.
    Rhea S
    Mod Healthc; 2009 Mar; 39(13):28-30. PubMed ID: 19405431
    [No Abstract]   [Full Text] [Related]  

  • 35. Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines.
    Wang N; Lipworth WL; Ritchie JE; Williams KM; Day RO
    Intern Med J; 2011 Apr; 41(4):314-20. PubMed ID: 20403068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The continuing search for proper perspective: whose reasonableness should be at issue in a prescription product design defect analysis?
    Cupp RL
    Spec Law Dig Health Care Law; 2000 Dec; (260):9-33. PubMed ID: 11149134
    [No Abstract]   [Full Text] [Related]  

  • 37. [The concern over better drugs].
    Janssen PA
    Verh K Acad Geneeskd Belg; 1982; 44(5-6):367-90. PubMed ID: 7184277
    [No Abstract]   [Full Text] [Related]  

  • 38. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages.
    Hunnisett-Dritz D
    Am J Health Syst Pharm; 2012 Oct; 69(19):1626, 1628. PubMed ID: 22997113
    [No Abstract]   [Full Text] [Related]  

  • 40. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.